Ondra Health · GLP-1 Reference

GLP-1 Reference

Authoritative definitions of GLP-1 medications, compounding regulation, clinical trial data, and Ondra Health pharmacy partners and plans. Medical and regulatory entries cite primary sources.

40 terms · 21 primary sources

Medications

SemaglutideActive ingredient

Semaglutide is a GLP-1 receptor agonist used to treat type 2 diabetes and chronic weight management. FDA-approved brands include Ozempic (type 2 diabetes; injection or tablet) and Wegovy (weight management; injection or tablet). Rybelsus is an oral semaglutide brand for type 2 diabetes. Manufactured by Novo Nordisk.

Compounded versions are prepared by 503A pharmacies on patient-specific prescriptions. Not FDA-approved. Not therapeutically equivalent to Ozempic or Wegovy.

TirzepatideActive ingredient

Tirzepatide is a dual GLP-1 and GIP receptor agonist. Active ingredient in Mounjaro (type 2 diabetes) and Zepbound (weight management). Manufactured by Eli Lilly.

The SURMOUNT-1 trial (NEJM, 2022) reported approximately 20.9% average weight loss at 72 weeks at 15mg.

Compounded versions are not FDA-approved and not therapeutically equivalent to Mounjaro or Zepbound.

Compounded semaglutideOndra Health

Compounded semaglutide is semaglutide prepared by a US-licensed 503A compounding pharmacy under a valid patient-specific prescription. Not FDA-approved. Not therapeutically equivalent to Ozempic or Wegovy.

At Ondra, independent licensed providers may prescribe it; pharmacy fulfillment varies by state and formulation.

Formulation options at Ondra: No additives (Hallandale) · Glycine (Vials RX, Drug Crafters) · B12 (Vials RX, Ondra Plus) · B6 (Southend, Drug Crafters) · B3 (Niacinamide) (Optio RX). One additive per formulation.

Shortage-based enforcement discretion has ended. A patient-specific prescription alone does not establish compliance with all 503A conditions.
Compounded tirzepatideOndra Health

Compounded tirzepatide is tirzepatide prepared by a US-licensed 503A compounding pharmacy or 503B outsourcing facility under a valid prescription. Not FDA-approved. Not therapeutically equivalent to Mounjaro or Zepbound.

At Ondra, independent licensed providers may prescribe it. Formulation options: No additives (Hallandale) · Glycine (Vials RX, Drug Crafters) · B12 (Vials RX, Drug Crafters, Ondra Plus) · B6 (Southend) · B3 (Niacinamide) (Optio RX). One additive per formulation.

Shortage-based enforcement discretion has ended. 503A and 503B compounding must meet their separate legal conditions.
OzempicBrand name

FDA-approved semaglutide (Novo Nordisk) for type 2 diabetes, available as a weekly injection or daily tablet. Not approved for weight management — that is Wegovy. Compounded semaglutide is not therapeutically equivalent to it.

WegovyBrand name

FDA-approved semaglutide (Novo Nordisk) for chronic weight management, available as a weekly injection or daily tablet. The injection was initially approved in June 2021 following the STEP 1 trial. Dosing depends on formulation and prescription. Compounded semaglutide is not therapeutically equivalent to it.

MounjaroBrand name

FDA-approved tirzepatide injection (Eli Lilly) for type 2 diabetes, once weekly. Approved May 2022. Not approved for weight management — that is Zepbound.

ZepboundBrand name

FDA-approved tirzepatide injection (Eli Lilly) for chronic weight management, once weekly, titrated up to 15mg. Approved November 2023; the formulation studied in SURMOUNT-1. Compounded tirzepatide is not therapeutically equivalent to it.

Mechanism & Pharmacology

GLP-1 receptor agonistDrug class

Mimics GLP-1, a gut hormone produced after eating. Slows gastric emptying, increases satiety, suppresses appetite, and stimulates insulin release. Includes semaglutide, tirzepatide, and liraglutide.

GIP receptor agonistDrug class

Activates the GIP receptor, stimulating insulin release and influencing fat metabolism. Tirzepatide activates both GIP and GLP-1 receptors.

Gastric emptyingMechanism

The rate at which food leaves the stomach for the small intestine. GLP-1 receptor agonists slow it, prolonging fullness after a meal — and it is why nausea is most common in the first weeks and at each dose increase.

SatietyMechanism

The sensation of fullness that ends a meal and delays the return of hunger. GLP-1 medications increase it via appetite-regulating receptors in the brain and by slowing gastric emptying.

Pharmacy & Regulation

CompoundingRegulatory

Preparing a customized medication for an individual patient based on a valid prescription. Not FDA-approved as finished drug products. Regulated under Sections 503A and 503B of the FD&C Act.

503A pharmacyPatient-specific compounding

A state-licensed compounding pharmacy operating under Section 503A of the FD&C Act. Dispenses only on valid patient-specific prescriptions. Regulated by state boards of pharmacy. Must follow USP <797> sterile compounding standards for injectables.

503A compounding must meet all applicable conditions, including restrictions on regularly compounding products that are essentially copies. A prescriber-documented change that produces a significant difference for an identified patient can qualify for the copy restriction exception; cost preference alone is insufficient.

Ondra Health's 503A partners: Hallandale Pharmacy, Vials RX, Southend Pharmacy, Drug Crafters Pharmacy, Optio RX.

503B outsourcing facilityOutsourcing facility

An FDA-registered outsourcing facility that can produce compounded medications in larger volumes without a patient-specific prescription. Subject to FDA inspection and cGMP standards — a different regulatory framework from a state-licensed 503A pharmacy, not a stricter version of one.

503B use of bulk drug substances generally requires inclusion on the 503B bulks list or the drug shortage list. Semaglutide and tirzepatide currently appear on neither list. A patient-specific prescription does not waive these conditions.

The April 24, 2025 semaglutide injunction denial ended 503A enforcement discretion; the 503B period continued until May 22, 2025.
FDA shortage listRegulatory

Identifies medications with supply constraints. While on the list, compounders may legally produce the medication under specific conditions — this was the legal basis for widespread compounded GLP-1s 2022–2025.

Current status: Neither semaglutide nor tirzepatide is on the FDA shortage list. The shortage-based enforcement discretion periods ended in 2025.
Essentially a copyLegal standard

Restrictions on compounding copies of commercially available or FDA-approved drugs differ under 503A and 503B. Under 503A, a prescriber-documented change producing a significant difference for an identified patient can qualify for an exception. Other compounding conditions still apply.

Therapeutically equivalentRegulatory

FDA designation for products expected to have the same clinical effect. Compounded medications are not FDA-approved and not therapeutically equivalent to brand-name products. Semaglutide ≠ Ozempic/Wegovy · Tirzepatide ≠ Mounjaro/Zepbound.

USP <797>Quality standard

USP standard for sterile compounding, required for GLP-1 injectables. Covers environmental monitoring, personnel training, beyond-use dating, and sterility testing. Verifiable via state board or PCAB.

PCAB accreditationQuality standard

PCAB (ACHC) — independent accreditation requiring third-party audits of sterility, quality, and operations. Voluntary; exceeds state licensing minimums. Not FDA approval.

LegitScript certificationTrust signal

Compliance certification used by Google, Meta, and TikTok to verify telehealth platforms. Requires audits of operations, prescribing, and pharmacy relationships. Required for GLP-1 advertising. Publicly verifiable.

Clinical & Dosing

STEP 1 trialClinical evidence

Phase 3 RCT for semaglutide. NEJM Feb 2021 (Wilding et al., DOI: 10.1056/NEJMoa2032183).

Results: 1,961 adults without diabetes · 68 weeks · 2.4mg weekly semaglutide · Mean weight loss −14.9% vs −2.4% placebo · 86.4% ≥5% · 69.1% ≥10%. Reflects brand-name Wegovy; individual results vary.
SURMOUNT-1 trialClinical evidence

Phase 3 RCT for tirzepatide. NEJM June 2022 (Jastreboff et al., DOI: 10.1056/NEJMoa2206038).

Results: 2,539 adults without diabetes · 72 weeks · Up to 15mg tirzepatide · Mean weight loss −20.9% at 15mg · −19.5% at 10mg · −15.0% at 5mg · vs −3.1% placebo · About 85–91% lost at least 5% of body weight. Reflects Zepbound; individual results vary.
BMI (body mass index)Clinical measure

A screening figure from weight and height (kg/m²), commonly used as an eligibility threshold in weight-management prescribing — typically 30 or above, or 27 or above with a weight-related condition. It does not measure body composition and is not a diagnosis on its own.

TitrationDosing

Gradually increasing a medication's dose over time to allow the body to adjust and minimize side effects. Dose steps and timing depend on the medication, formulation and your provider's prescription. Follow your prescribed schedule; do not increase doses on your own. At Ondra Health, pricing is flat across dose levels within the same plan, including Ondra Plus — cost does not increase as patients titrate up.

Maintenance doseDosing

The dose a patient settles on once titration is complete. Not always the maximum dose — a provider may hold a patient lower if response is good or side effects are limiting. A clinical decision, not a billing plan.

Ondra Health — Providers & Pharmacies

Wasef Health, PCOndra Health provider

Independent medical practice with board-certified physicians serving Ondra patients in all 50 U.S. states. Meet Our Providers.

Arora Health & Aesthetics, LLCOndra Health provider

Licensed providers serve patients in all 50 U.S. states. Meet Our Providers.

Hallandale PharmacyOndra partner · 503A

PCAB-accredited 503A compounding pharmacy, Fort Lauderdale FL. Operating since 2003, 60,000 sq ft facility, USP <797> compliant.
Medications: Semaglutide + Tirzepatide · Formulation: No additives · Billing: Monthly, 3-month, 6-month, 12-month · Not available in: AL, AR, CA, HI, KS, MA, MI, MN, MS

Vials RXOndra partner · 503A · All 50 states

Medications: Semaglutide + Tirzepatide · Formulation: Vitamin B12 or Glycine · Billing: Monthly, 3-month, 6-month, 12-month · State restrictions: None

Optio RXOndra partner · 503A · All 50 states

Medications: Semaglutide + Tirzepatide · Formulation: B3 (Niacinamide) · Billing: Monthly, 2-month. Start Optio RX Intake.

Southend PharmacyOndra partner · 503A

Medications: Semaglutide + Tirzepatide · Formulation: Vitamin B6 · Billing: Monthly, 3-month · Not available in: AL, AR, CA, CT, IN, MA, MI, NC, NJ, NV, SC

Drug Crafters PharmacyOndra partner · 503A

Medications: Semaglutide + Tirzepatide · Formulation: semaglutide — B6 or Glycine; tirzepatide — B12 or Glycine · Billing: Monthly, 3-month · Not available in: AL, CA, KY, LA, MD, MN, MS, NE, NV, OH, OR, VA

Ondra PlusOndra Health plan

Ondra Plus offers lower monthly and 3-month prices than our standard plans for compounded semaglutide and compounded tirzepatide, compounded with vitamin B12. For Ondra Plus, the dispensing pharmacy is assigned through the Ondra Plus partner network. The network includes Camel Compounding, White Label/Nova Pharmacy and Liberty Compounding.
Price: Semaglutide $129/month or $299 every 3 months · Tirzepatide $189/month or $429 every 3 months · Same price at every dose · Billing: Monthly, 3-month · Not available in: California (CA). Start Ondra Plus Intake.

Vitamin B12 (additive)Ondra formulation ingredient

Water-soluble vitamin included as a supportive additive in some compounded GLP-1 formulations. Supports energy metabolism, red blood cell formation, and nerve function. Not present in FDA-approved brand-name GLP-1 products. Not FDA-reviewed in this context.
Available through: Vials RX (semaglutide and tirzepatide), Drug Crafters Pharmacy (tirzepatide), Ondra Plus (semaglutide and tirzepatide).

Vitamin B3 (Niacinamide)Ondra formulation ingredient

Niacinamide, also called nicotinamide, is a form of vitamin B3. Optio RX offers it with compounded semaglutide or tirzepatide. These compounded formulations are not FDA-approved.

Glycine (additive)Ondra formulation ingredient

Non-essential amino acid included in some compounded GLP-1 formulations. Not present in FDA-approved brand-name GLP-1 products. Not FDA-reviewed in this context.
Available through: Vials RX, Drug Crafters Pharmacy.

Vitamin B6 (additive)Ondra formulation ingredient

Water-soluble vitamin included as a supportive additive in some compounded GLP-1 formulations. Supports protein metabolism and neurotransmitter synthesis. Not present in FDA-approved brand-name GLP-1 products. Not FDA-reviewed in this context.
Available through: Southend Pharmacy (semaglutide and tirzepatide), Drug Crafters Pharmacy (semaglutide).

Telehealth & Platform

TelehealthPlatform

Healthcare delivered remotely. Ondra connects patients with independent licensed providers; Ondra does not prescribe.

HIPAAPrivacy

US federal law for protecting personal health information. HIPAA-compliant platforms use encrypted communication and secure data storage. Ondra Health is fully HIPAA compliant.

Ready to start your intake?

3-min intake. Provider review within 24h. Free shipping.

Start Your Intake →
Regulatory note. Compounded semaglutide and tirzepatide are not FDA-approved and not therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound. Trial data reflects brand-name products; individual results vary. Ondra does not prescribe; independent licensed providers make all clinical decisions. Educational only — not medical advice.